# A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)

> **NCT04710576** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Syndax Pharmaceuticals** · enrollment: 241 (actual)

## Conditions studied

- Chronic Graft-versus-host-disease

## Interventions

- **DRUG:** Axatilimab

## Key facts

- **NCT ID:** NCT04710576
- **Lead sponsor:** Syndax Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-03-04
- **Primary completion:** 2023-04-07
- **Final completion:** 2027-09
- **Target enrollment:** 241 (ACTUAL)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04710576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04710576, "A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04710576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*